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We present the case of a 77︲year-old Japanese man diagnosed with lung squamous cell carcinoma with 
mediastinal lymph node metastasis.  He was treated with induction chemoradiotherapy for T1bN2M0 
stage IIIA disease.  Considering his age,  we selected S-1 as the chemotherapeutic drug.  Observing an 
objective response with no severe adverse events,  we performed a left upper lobectomy with sleeve 
resection of the pulmonary artery.  No residual tumor cells were found in the resected specimens,  and 
no critical complication was observed in the clinical course.  This case suggests that induction chemo-
radiotherapy using S-1 combined with concurrent radiation followed by surgery can be a therapeutic 
option for elderly patients with locally advanced non-small-cell lung cancer.
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T he standard treatment of locally advanced non-small-cell lung carcinoma (NSCLC) with medi-
astinal lymph node metastasis is deﬁnitive chemora-
diotherapy with or without consolidation che mo therapy 
﹇1﹈.  A recent randomized phase III trial reported by 
Albain et al.  did not demonstrate that surgery after 
induction chemoradiotherapy improves prognosis 
compared with deﬁnitive chemoradiotherapy.  On the 
other hand,  the possible advantages of surgical resec-
tion for selected patients with N2 disease were sug-
gested in the same trial ﹇2﹈.  The standard regimen of 
chemoradiotherapy is a platinum-based combination,  
but there is no evidence that aggressive treatments 
used for young patients improve survival in elderly 
patients ﹇3, 4﹈.
　 We recently reported that concurrent treatment 
with S-1 and thoracic radiation is a feasible option for 
NSCLC in elderly patients (aged ＞75 years),  show-
ing an acceptable response with manageable toxicity 
﹇5, 6﹈.  Here we describe the case of an elderly patient 
who was successfully treated with induction chemora-
diotherapy using S-1 followed by surgery.
Case Report
　 A 77︲year-old Japanese man with a history of 
hypertension and diabetes was admitted to our hospital 
for the treatment of NSCLC in February 2014.  
Image analyses showed a 2.6︲cm tumor in the left 
upper lobe and the positive mediastinal lymph node 
(Fig.  1).  A transbronchial lung biopsy demonstrated 
squamous cell carcinoma,  and endobronchial ultra-
sound-guided transbronchial needle aspiration from the 
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mediastinal lymph node revealed metastasis in the left 
lower paratracheal lymph node.  Based on these ﬁnd-
ings,  we diagnosed this case as T1bN2M0 stage IIIA 
squamous cell carcinoma.
　 Considering the patientʼs age and good performance 
status (PS1),  we decided to perform induction chemo-
radiotherapy using S-1 as the chemotherapeutic agent,  
followed by surgery.  The induction therapy involved 
S-1 administration (oral S-1 at 40mg/m2 twice daily 
from days 1 to 14 and 29 to 42) with concurrent radia-
tion (2 Gy/day; total 46 Gy).  This regimen was based 
on our previous phase I study,  except that the radia-
tion dose was reduced in the present induction set-
tings ﹇5, 7﹈.
　 The induction chemoradiotherapy yielded a radio-
logical partial response (Fig.  2).  The adverse eﬀects 
esophagitis (grade 1) and radiation pneumonitis 
(grade 1) occurred and were treated conservatively.  
On day 35 after the end of the induction therapy,  we 
performed a left upper lobectomy with sleeve resec-
tion of the pulmonary artery containing branches to the 
superior division and systemic lymph node dissection 
using a median sternotomy with fourth intercostal 
thoracotomy.
　 Microscopic examination of the resected specimens 
showed no residual tumor cells,  demonstrating a 
pathological complete response.  The postoperative 
course was uneventful except for atrial ﬁbrillation,  
which was treated conservatively.  Adjuvant therapy 
was not performed.  The patient has been active daily 
with a stable PS1 condition and disease-free status for 
1 year after surgery.
Discussion
　 Previous studies had indicated that radiotherapy 
was considered the standard treatment for elderly 
patients with locally advanced NSCLC ﹇3, 8﹈.  
However,  the clinical outcome was not satisfactory,  
with a median survival time of 13.1 months for 
patients aged ＞70 years ﹇8﹈.  In anticipation of the 
increased population of elderly NSCLC patients with 
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Fig. 1　 Image analyses before induction chemoradiotherapy.  (A) 
A CT scan of the chest.  (B) A PET-CT scan.  A lung tumor invading 
the pulmonary artery with a swollen left lower paratracheal lymph 
node is visible (strong uptake of 18F-ﬂuorodeoxyglucose).
Ａ
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Fig. 2　 Image analyses after induction chemoradiotherapy.  (A) A 
CT scan of the chest.  (B) A PET-CT scan.  The lung tumor and 
swollen lymph node are remarkably reduced in size (decreased 
uptake of 18F-ﬂuorodeoxyglucose).  Radiation pneumonitis is visible 
in the left lower lobe.
good PS,  curative treatment strategies for elderly 
patients should be developed.  A recent study con-
ducted by the Japan Clinical Oncology Group showed 
that daily low-dose carboplatin with radiotherapy is 
superior to radiotherapy alone in patients aged ＞70 
years with locally advanced NSCLC ﹇9﹈.
　 S-1,  an oral anticancer ﬂuoropyrimidine derivative,  
is considered an active single agent against NSCLC,  
exhibiting a radiosensitizing eﬀect and few adverse 
events ﹇5﹈.  Recent phase I and phase II studies con-
ducted by one of the authors (K. K. ) showed the feasi-
bility of concurrent chemoradiotherapy with S-1 and 
thoracic radiation,  with an acceptable toxicity and 
medial progression-free survival time (13.1 months at 
a median follow-up time of 23.7 months) in patients aged 
＞75 years with locally advanced NSCLC ﹇5, 6﹈.  
We reduced the radiation dose to 46 Gy in the present 
induction settings.
　 From the viewpoint of surgery,  one of the desired 
eﬀects of induction therapy is a reduction in tumor 
volume to facilitate surgical manipulations.  This eﬀect 
also helps surgeons to determine the appropriate sur-
gical margin.  On the other hand,  Albain et al. 
reported a high mortality rate of pneumonectomy after 
chemoradiotherapy and suggested that trimodality 
treatment could be beneﬁcial if a complete resection 
with lobectomy can be done after chemoradiotherapy 
﹇2﹈.  In our patientʼs case,  the primary tumor invaded 
the left pulmonary artery,  advancing to its ﬁrst 
branch.  While we successfully performed sleeve 
resection of the pulmonary artery to avoid pneumonec-
tomy,  it is possible that the pneumonectomy would 
have been unavoidable if an initial surgery had been 
performed or if the induction chemotherapy had not 
reduced the tumor size.  Even in this situation,  the left 
pneumonectomy should be ﬁnally performed after mak-
ing a maximum eﬀort to avoid a pneumonectomy,  in 
order to reduce critical complications and maintain the 
patientʼs activities of daily living after surgery.
　 The short follow-up period is one of the limitations 
of this case that should be considered before the use-
fulness of our strategy can be conﬁrmed from the 
viewpoint of survival.  While further follow-up is nec-
essary,  no critical complication has been observed so 
far,  suggesting the feasibility of this modality.
　 In conclusion,  our experience suggests that induc-
tion chemoradiotherapy using S-1 with concurrent 
radiation followed by surgery can be a therapeutic 
option for selected elderly patients with locally 
advanced NSCLC.
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